Literature DB >> 2524206

Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.

S Madden1, D J Back, C A Martin, M L Orme.   

Abstract

1. The intestinal mucosal metabolism of the progestogen oral contraceptive desogestrel (Dg) has been studied in vitro using the Ussing chamber technique. Histologically normal ileum or colon was obtained from eight patients undergoing various resections. The mucosal sheets were mounted between two perspex chambers. 2. Two hours after addition of [3H]-Dg (0.2 microCi; 100 ng) to the mucosal chamber, more than 90% of the steroid was present in that chamber. In studies with colon, metabolite analysis showed that 55.4 +/- 11.7% (mean +/- s.d.; n = 6) of drug present was Dg, 28.9 +/- 11.4% as unconjugated Phase I metabolites, 13.3 +/- 2.6% as sulphate conjugates and 2.5 +/- 1.5% as glucuronide conjugates. 3. By co-chromatography with authentic metabolites and mass spectrometry, it was shown that 3-keto desogestrel is formed in the mucosa. This is the active metabolite of desogestrel. A large peak of radioactivity did not co-chromatograph with any known metabolites and has been tentatively identified as ring hydroxylated products of 3-keto desogestrel. 4. The effect of the synthetic oestrogen ethinyloestradiol (EE2) on the metabolite profile of Dg was studied. In the presence of increasing concentrations of EE2 (100 ng, 1 and 10 micrograms), there was competition for sulphation such that the sulphate fraction decreased by 32, 49 and 48% respectively. 5. The results of this study indicate substantial first pass metabolism of desogestrel by the gut mucosa with evidence for the formation of the active metabolite. The extent of phase I metabolism is unusual.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Desogestrel--administraction and dosage; Developed Countries; Ethinyl Estradiol--side effects; Europe; Examinations And Diagnoses; Family Planning; Histology; In Vitro; Laboratory Examinations And Diagnoses; Metabolic Effects; Northern Europe; Physiology; Research Methodology; Steroid Metabolic Effects; United Kingdom

Mesh:

Substances:

Year:  1989        PMID: 2524206      PMCID: PMC1379826          DOI: 10.1111/j.1365-2125.1989.tb05368.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.

Authors:  D J Back; S F Grimmer; N Shenoy; M L Orme
Journal:  Contraception       Date:  1987-06       Impact factor: 3.375

2.  Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel.

Authors:  H G Hasenack; A M Bosch; K Käär
Journal:  Contraception       Date:  1986-06       Impact factor: 3.375

3.  Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. Pharmacokinetics after an oral dose.

Authors:  L Viinikka; O Ylikorkala; R Vihko; H P Wijnand; M Booij; F van der Veen
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

4.  Active transport of sodium by human colon in vitro.

Authors:  G F Grady; R C Duhamel; E W Moore
Journal:  Gastroenterology       Date:  1970-10       Impact factor: 22.682

5.  Biological effects of a new and potent progestagen. A clinical study.

Authors:  L Viinikka; O Ylikorkala; S Nummi; P Virkkunen; T Ranta; U Alapiessa; R Vihko
Journal:  Acta Endocrinol (Copenh)       Date:  1976-10

6.  The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans.

Authors:  D J Back; A M Breckenridge; M MacIver; M Orme; H S Purba; P H Rowe; I Taylor
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

7.  Sulphation and glucuronidation of ethinyloestradiol in human liver in vitro.

Authors:  G M Pacifici; D J Back
Journal:  J Steroid Biochem       Date:  1988-09       Impact factor: 4.292

8.  Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man.

Authors:  F Hartmann; L D Gruenke; J C Craig; D M Bissell
Journal:  Drug Metab Dispos       Date:  1983 May-Jun       Impact factor: 3.922

9.  Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers.

Authors:  S M Rogers; D J Back; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 10.  Review: first-pass metabolism by the gastrointestinal mucosa.

Authors:  D J Back; S M Rogers
Journal:  Aliment Pharmacol Ther       Date:  1987-10       Impact factor: 8.171

  10 in total
  8 in total

1.  The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.

Authors:  Tuomas Korhonen; Ari Tolonen; Jouko Uusitalo; Stefan Lundgren; Jorma Jalonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Cyclosporin metabolism by the gastrointestinal mucosa.

Authors:  J F Tjia; I R Webber; D J Back
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases.

Authors:  Anne Caroline S Barbosa; Ye Feng; Chaohui Yu; Min Huang; Wen Xie
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-03-18       Impact factor: 4.481

Review 5.  Comparative pharmacology of newer progestogens.

Authors:  H Kuhl
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 6.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

7.  Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers.

Authors:  María Ángeles Pena; Emilio Sanz; Silvia Francisco; Ainhara Alonso; Zurine Abajo; Izaskun Felipe; Jaume Pascual; Digna Tost; Sandra Bailac
Journal:  Sci Pharm       Date:  2012-03-01

8.  Pharmacokinetics of Oral Levonorgestrel in Women After Roux-en-Y Gastric Bypass Surgery and in BMI-Matched Controls.

Authors:  Charlotte Ginstman; Helena Kopp Kallner; Johanna Fagerberg-Silwer; Björn Carlsson; Andreas Ärlemalm; Ylva Böttiger; Jan Brynhildsen
Journal:  Obes Surg       Date:  2020-06       Impact factor: 4.129

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.